Media OutReach
Bora Pharmaceuticals Exits Integration Phase with Sequentially-Improved Gross and Operating Margins
Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio
HONG KONG SAR – Media OutReach Newswire – 14 May 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for first quarter of 2025.
- Fueled by expanded capacity and new dosage forms, Bora’s CDMO business delivered a record high quarter, up 52.4% YoY and 3.0% QoQ.
- As part of Bora’s long-term strategic growth plan, the Company is moving forward with a phased investment of tens of thousands US dollars to unlock the untapped potential of Maple Grove facility. This build-out is designed to enhance capabilities in oral solid dose and sterile manufacturing, strengthening the ability to support customer demand and scale future programs.
- Pharma Sales revenues rose 82.0% YoY based on reported unaudited monthly sales, driven by strong performance from the vigabatrin franchise, which includes three dosage forms. Notably, VIGAFYDE captured over 70% share in the new patient segment.
- Due to the completion of Plymouth area decommissioning, consolidated revenues for 1Q25 was NT$4.48 billion, a NT$350 million reversal from the unaudited monthly disclosures, all of which was attributed to the pharma sales segment.
- Despite margin pressure from partial maintenance shutdowns at the Maryland sterile injectable site in early January and softening demand for generic product dexlansoprazole (DLS), product mix improvement from growing specialty portfolio lifted gross margin from the low of 4Q24 to 42.2% in 1Q25. Tech transfer for 6 Upsher-Smith generic products to cost-competitive sites within Bora network remains on track, with full transfer expected by year-end to support further margin recovery.
- EPS from continuing operations reached NT$26.54, reflecting NT$2.44 billion of net non-operating income from the divestment of Bora Biologics and recognition of losses of Tanvex Biopharm. However, the decommissioning of the Plymouth area negatively impacted EPS by NT$12.99, resulting in a reported EPS of NT$13.55. Share capital increased 0.4% during the quarter from employee stock option exercises and convertible bond conversions.
- DLS competitors began exiting the market in early 2Q25 due to supply chain hiccups, creating new opportunities for Bora to increase share and drive recovery momentum.
- The Group remains optimistic that its first quarter restructuring efforts will increase the long-term value of its recent acquisitions, including unlocking NT$600 million in capital in 2025. CDMO business growth will be further accelerated with strategic U.S.-based capability and capacity.
The closure of Plymouth area was completed ahead of schedule during the quarter and the area has thus been reclassified as discontinued operation in our quarterly financial statements altogether. From an operational standpoint, Bora has discontinued 15 products in the U.S. generics market along with the restructure, with an additional 6 products transferred to more cost-efficient manufacturing sites within the Group. On the financial side, discontinued operation resulted in a negative impact of approximately NT$1.34 billion, including overhead, inventory and equipment write-downs as well as severance-related expenses.
Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by over NT$5.0 billion cash on hand. At Maple Grove, 4 global pharmaceutical clients are currently in advanced discussions regarding CAPEX investments which we view as a strong validation of the site’s value and strategic fit. While the timeline for full deployment spans several years, we are approaching this expansion with operational discipline and commercial alignment to ensure its success over time.
On pharma sales side, Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). This recovery underscores Bora’s agility and the resilience of the dual-engine strategy. Furthermore, we have successfully consolidated distribution network for specialty drugs. Bora expects its pediatric spasm product, VIGAFYDE (the 505(b)(2) oral solution), to extend its success in the new patient market into the switch segment in the very near future, supporting future margin and operational leverage expansion.
We continue executing on our goals to scale up, achieve more and integrate smarter, ensuring that both internal and external clients benefit from cost-efficient, regionally aligned manufacturing. By extending the strength of our dual-engine model, we believe Bora shall continue to create above-average total shareholder return.”
Global CDMO Operations
Global CDMO Operations (excluding internal orders) delivered record-high revenues of NT$1.90 billion in the first quarter, up 52.4% YoY and representing approximately 39% of total revenue. Including internal orders, CDMO revenue reached NT$2.89 billion. A total of 600 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 30%, demonstrating strong clientele and advantage of scale. Bora CDMO continues to be a trusted partner for biotech and pharmaceutical innovators.
- In 1Q25, the small molecule CDMO pipeline added US$123 million in potential orders and US$78 million in backlog, both marking historic highs.
- CAPEX progress across sites reached approximately 50%, focused on debottlenecks, efficiency improvement, capacity increase and infrastructure upgrade to align with client and product needs. Flex Pro line at the Maryland sterile injectable facility was completed ahead of schedule and is expected to begin operations in early Q3.
- Maple Grove launched its first CDMO project during the quarter and is currently negotiating with potential clients while evaluating CAPEX plans for differentiated dosage platforms. Overall, North American capacity transformation is progressing as planned.
- Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients. Bora and Tanvex are actively pursuing U.S.-based commercial-scale manufacturing orders with a comprehensive one-stop service model.
Pharma Sales Operations
Pharma Sales Operations revenue reached NT$2.93 billion, representing 82.0% YoY growth and contributing approximately 61% of total revenue based on unadjusted numbers.
- As the Upsher-Smith team continue to consolidate distributors for specialty drugs, we saw early signs of positive engagement from both market and payer channels at the end of the first quarter. Following the 2024 integration of TWi, Upsher-Smith and Pyros teams, Bora has established a focused pipeline in CNS specialty areas. The company expects to file its first self-developed 505(b)(2) submission for infantile spasms (Stiripentol) with the U.S. FDA by year-end, alongside other pipeline developments.
- Pediatric epilepsy and TSC-related rare diseases represent the first wave of Bora’s pharma sales transformation targets. In addition to reducing over-reliance on generics, high-value rare disease and specialty drugs benefit from strong regulatory and payer support in the specialty pharmacy channel. These markets are less competitive with stable price, and offer targeted access to patient populations, allowing for meaningful long-tail value creation.
Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company’s Q1’25 financial and business results and outlook.
English Online Earnings Presentation Link: https://www.zucast.com/event/54SiM5il/subscribe/create
The 2025 Annual General Shareholders’ Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.
Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.
Q2 2025: Expected in the 3rd week of August 2025
Q3 2025: Expected in the 3rd week of November 2025
Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracorpcdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
The Secret to a Decade of Loyalty
A decade of consistent customer trust speaks for itself. XIXILI’s seamless panties have earned a loyal following of women who return to the same style, year after year.
Whether it’s a breathable cotton panty for everyday basics or a sleek seamless style for fitted outfits, comfort remains the priority. The appeal comes down to the essentials: no visible panty lines, no adjusting throughout the day, and lightweight comfort that holds up from morning to night. For women juggling busy schedules, that kind of reliability makes all the difference.
“Our customers tell us these are the panties they don’t have to think about,” says Tara Tan, spokesperson for XIXILI. “They just work. That’s why women keep coming back.”
Designed for Every Body, Built to Last
The Full Coverage Mid-Rise Knitted Boyleg Panty delivers moderate coverage with a relaxed fit, suited for those who want fuss-free comfort. The High-Waist Knitted Boyleg Panty sits higher on the waist with gentle tummy smoothing, a go-to for wearing beneath tailored pieces and fitted silhouettes.
The Lightweight Seamless Microfiber Panty remains the star of the range. Its soft microfiber construction sits flat against the skin, creating an invisible finish under any outfit. A bestseller for ten consecutive years, this fan-favourite now comes in new colours, giving loyal fans a reason to refresh their collection.
The Foundation of Every Outfit
What sits beneath an outfit often sets the tone for the entire day. It’s the layer no one sees but everyone feels, allowing women to move through their routines with confidence, whether at work, running errands, or out with friends.
XIXILI’s decade-long bestseller continues to deliver on that promise. With new colours now available, updating the essentials is as effortless as the panties themselves.
To discover the full panties collection, visit XIXILI’s website to shop online with delivery to Singapore, or find your nearest XIXILI boutique across Malaysia.
Hashtag: #XIXILI #SGLingerie
https://www.xixili-intimates.com/sg/
https://www.facebook.com/XIXILI.OfficialFanPage/
https://www.instagram.com/xixili_intima/
https://www.tiktok.com/@xixili_intima?
https://www.youtube.com/user/xixilipage
The issuer is solely responsible for the content of this announcement.
About XIXILI
A proudly Malaysian brand, XIXILI offers fashion lingerie and shapewear that combines elegance with all-day comfort. With one of the most inclusive sizing ranges between A to I cups and 65 to 110cm band sizes, XIXILI designs for every body type. The brand is known for its expert fitters, premium materials, and dedication to helping women feel confident and supported.
XIXILI is also the first Malaysian lingerie brand to launch a 3D Avatar Try-On Tool, enabling women to virtually try on lingerie tailored to their unique body type and measurements. From everyday basics to occasion-ready pieces, XIXILI celebrates the beauty of real bodies, every day.
Media OutReach
Huawei, Meralco, and SANXING Ningbo Launch Intelligent Distribution Solution and Lighthouse Initiative
Communication, digitalization, and AI: Emerging cornerstones of future power systems that will accelerate the intelligent evolution of distribution networks
David Sun, CEO of Huawei’s Electric Power Digitalization BU, highlighted four drivers for energy transition: green energy and diversity, resilient grids, transparent distribution, and load electrification. He called for policy changes toward dispatch-market coordination. He also emphasized that communication, digitalization, and AI are becoming core production systems, requiring stronger capabilities in digital transformation, cybersecurity, and sustainable development.
At the forum, Mr. Sun unveiled the White Paper on Communication Target Networks for the Future Power System, introducing a pioneering architecture that features an intelligent and robust main network, integrated medium-voltage and transparent low-voltage networks, high-speed secure connectivity, and space-ground integration. The paper also outlines key tech trends, from optical and wireless to carrier and satellite communications, and underscores their transformative value.
Huawei highlighted its focus on intelligence and digitalization, working with industry players to drive power transformation. Global industry leaders also shared their insights: Al’Louise van Deventer (Technology and Engineering General Manager, Eskom) on future-ready digital practices; Momar Awa Sall (Transmission Grid Director, Senelec) on private wireless networks accelerating power modernization; Deniz COSKUN (Deputy General Manager, TEİAŞ) on restructuring communication networks for grid resilience; and Andy Liu (Overseas Solutions and Marketing Director, SANXING Ningbo) on the application of Huawei IDS.
Global industry leaders and partners join to explore the future of power systems
Power distribution networks are evolving from mechanized to automated and intelligent systems, driving technological and business model innovation. Despite creating new challenges for O&M, they have unlocked further opportunities for improving grid reliability and resource allocation.
At the forum, Huawei, Meralco, and SANXING Ningbo, unveiled the IDS that delivers four core capabilities—reliable communication, edge computing, cloud-edge collaboration, and low-voltage transparency—based on a cloud-pipe-edge-pipe-device architecture. It enables an intelligent low-voltage (400 V) distribution network with controllable line loss, visualized distribution rooms, and manageable renewables, transforming fragmented digital silos into open, integrated digital systems. The three companies also announced a lighthouse showcase initiative, sharing replicable and scalable digital transformation best practices.
Advancing digital and intelligent integration for a greener, more reliable grid
Communication, digitalization, and AI are at the heart of future power systems. Huawei will deepen R&D in digital, intelligent technologies, integrating advanced intelligence into power production. Together with global partners, Huawei is committed to developing with the power industry toward greater reliability, stronger security, and a low-carbon future.
Hashtag: #Huawei
The issuer is solely responsible for the content of this announcement.
Media OutReach
Thailand Unveils Public–Private Alliance to Lead Asia’s Wellness Economy Revolution BDMS Wellness Clinic Rises as National Orchestrator of a Science-Powered, Luxury-Integrated Wellness Ecosystem
A Multi-Sector Coalition at Unprecedented Scale
Led and orchestrated by BDMS Wellness Clinic, this alliance represents one of the most holistic cross-industry coalitions in Thailand’s health and tourism landscape. As the central integrator, BDMS Wellness Clinic unites public agencies, aviation leaders, hospitality icons, financial institutions, and global biotechnology innovators into a single, strategically aligned Wellness Ecosystem. Key national partners include the Thailand Convention and Exhibition Bureau (TCEB), Thailand Privilege Card Co., Ltd., and the Thai Spa Association, with regional connectivity strengthened by Bangkok Airways. The luxury and lifestyle dimension features Sri panwa Phuket, CELES SAMUI, Mövenpick BDMS Wellness Resort Bangkok, Dusit Thani Bangkok, King Power Corporation, Siam Piwat Co., Ltd., and Lancôme by L’Oréal Thailand.
Healthcare infrastructure and precision diagnostics are reinforced by National Healthcare Systems (N Health), enabling advanced laboratory networks, cross-border clinical data integration, and continuity of care. This capability is further elevated through collaboration with global medical and biotechnology leaders — Straumann Group in advanced dental innovation, Illumina in genomic sequencing, Abbott in precision diagnostics, and Gene Solutions in next-generation molecular testing.
Through this convergence of genomics, biomarker analytics, regenerative technology, and preventive medicine, BDMS Wellness Clinic delivers data-driven health optimization—from early disease detection and biological age assessment to personalized longevity programs. Together, under BDMS Wellness Clinic’s leadership, these partners form a fully integrated, science-powered ecosystem that transforms preventive care into measurable outcomes—firmly positioning Thailand at the forefront of Asia’s Wellness Economy.
From Healthcare Provider to National Orchestrator
BDMS Wellness Clinic has evolved beyond the traditional role of a healthcare provider to become the strategic integrator of Thailand’s Wellness Ecosystem—serving as the “National Orchestrator” uniting public institutions, private enterprises, academia, and global partners under one coordinated vision. Its mission extends far beyond treatment: to optimize healthspan, precise longevity science, and build a sustainable ecosystem where wellness becomes both a national economic engine and a form of diplomatic soft power. By synchronizing infrastructure, policy, aviation, hospitality, finance, and biotechnology, BDMS Wellness Clinic is repositioning Thailand from a destination known primarily for leisure and elective care into a global epicenter of evidence-based preventive medicine and measurable health optimization.
BDMS Wellness Clinic with Wellness Literacy: The Foundation of Sustainable Global Leadership
Sustainable global leadership demands more than world-class facilities—it requires a new generation of visionaries, scientists, and industry leaders equipped to redefine the future of health. BDMS Wellness Clinic has therefore launched a transformative Wellness Literacy strategy designed to cultivate world-class human capital, elevate professional standards, and shape a knowledge-driven ecosystem that positions Thailand at the forefront of preventive medicine and longevity science in Asia and beyond.
Through strategic alliances with leading institutions—including Thammasat University and King Mongkut’s Institute of Technology Ladkrabang (KMITL) in Thailand, as well as the University of Sharjah (UAE) and Singapore Management University (SMU)—BDMS Wellness Clinic is co-developing advanced curricula in preventive medicine, longevity science, and wellness management. These collaborations are establishing a new Asian benchmark for preventive healthcare education while producing a future-ready workforce for the global wellness economy. Beyond academia, BDMS Wellness Clinic is empowering entrepreneurs and industry operators nationwide, equipping hospitality, spa, and lifestyle businesses with measurable wellness standards—elevating Thailand’s entire value chain to international levels of excellence.
From Thailand to the World: BDMS Wellness Clinic’s Global Wellness Network
Extending its ecosystem beyond national borders, BDMS Wellness Clinic has forged strategic alliances with Neem Hospital—a leading private healthcare institution in the Sultanate of Oman known for its integrated clinical services and patient-centered care—and the MODAWI Platform, a digital health coordination platform that streamlines medical referrals, clinical data exchange, and cross-border care navigation.
Together, these partnerships establish a seamless referral and clinical integration network linking the GCC region with BDMS Wellness Clinic services. By combining hospital-based clinical excellence with digital health infrastructure, the model ensures continuity of care across borders—enabling patients to transition smoothly from initial consultation in the Middle East to advanced diagnostics, genomics, and longevity programs.
The Proof of Concept: “The Journey Within”
The flagship initiative, “The Journey Within,” translates vision into execution—serving as the living blueprint of the Wellness Ecosystem envisioned by BDMS Wellness Clinic. Anchored in three seamlessly integrated pillars—Travel, Stay, and Scientific Wellness—the concept redefines how a nation can deliver holistic, outcome-driven health experiences.
- Travel: Luxury aviation partnerships, streamlined entry facilitation, and curated collaborations with lifestyle partners—ensuring effortless arrival and a seamless transition into an elevated wellness journey.
- Stay: Curated luxury hospitality designed to immerse guests in restorative comfort and elevated living.
- Scientific Wellness: Technological diagnostics, genomics, and precision-driven longevity programs delivering measurable health transformation.
For more information about The Journey Within, click https://bdmswellness.co/40LNk4v
Hashtag: #BDMSWellnessClinic #สุขภาพที่ดีเริ่มที่การป้องกัน #LiveLongerHealthierHappier #PreventiveMedicine #LifestyleMedicine #ScientificWellness #WellnessHubThailand
https://www.bdmswellness.com/en
https://www.linkedin.com/company/bdmswellnessclinic/
https://www.facebook.com/bdmswellnessclinicinternational
https://www.instagram.com/bdmswellnessinternational/?hl=en
The issuer is solely responsible for the content of this announcement.
BDMS Wellness Clinic
BDMS Wellness Clinic, a pivotal entity within the Bangkok Dusit Medical Services (BDMS) network—Thailand’s leading operator of private hospitals—embodies a forward-thinking approach to healthcare, prioritizing prevention over cure. Specializing in early detection and prevention of diseases, our clinic offers a holistic suite of services, including advanced dental care and fertility treatments. Leveraging cutting-edge science and technology, BDMS Wellness Clinic not only anticipates future health challenges but also enhances the quality of life, marking its stature as Asia’s premier healthcare facility dedicated to elevating both mental and physical well-being.
For more details:
Facebook: Facebook.com/BDMSWellnessClinic
Instagram: @BDMSWellness
Media Inquiries: Media Inquiries: Please contact Marketing and Communication Department, BDMS Wellness Clinic Co. Ltd.
Chanokphat Pawangkanan 098-369-5963 Email: ch***********@**********ss.com
Sasiwimol Techawanto 092-807-5893 Email: 
Sa**********@**********ss.com
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn